Clinical Trial

Evaluation of Serum Ceramides C16, C24, and Sphingosine-1-Phosphate (S1P) in Patients With Acne Vulgaris

Study acronym: CER-S1P-ACNE
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 26, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
Acne vulgaris is a common chronic inflammatory skin disorder that affects adolescents and young adults. Recent research has shown that lipid mediators, including ceramides and sphingolipids, play an important role in maintaining skin barrier function and inflammation. This study aims to evaluate the serum levels of ceramide C16, ceramide C24, and sphingosine-1-phosphate (S1P) in patients with acne vulgaris and compare them to healthy controls. The goal is to explore their possible role in the pathogenesis and severity of acne. Blood samples will be collected from participants, and quantitative analysis will be performed using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Trial Details
NCT Number NCT07250880
Lead Sponsor Sohag University
Conditions Acne Vulgaris
Enrollment 80 participants
Start Date 2025-11
Primary Completion 2026-06 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2025-11-26